Updating results

516 results

Sort: Relevance | Date

Ticagrelor for the treatment of acute coronary syndromes (TA236)

Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes

Technology appraisal guidance Published October 2011

Prucalopride for the treatment of chronic constipation in women (TA211)

Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women

Technology appraisal guidance Published December 2010

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

Evidence-based recommendations on aripiprazole (Abilify) for treating schizophrenia in people aged 15 to 17 years

Technology appraisal guidance Published January 2011

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance Published March 2011

Bortezomib monotherapy for relapsed multiple myeloma (TA129)

Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)

Technology appraisal guidance Published October 2007

Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published August 2007

Varenicline for smoking cessation (TA123)

Evidence-based recommendations on varenicline (Champix) to help people stop smoking

Technology appraisal guidance Published July 2007

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)

Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published February 2007

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published August 2007

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Adalimumab for the treatment of adults with psoriasis (TA146)

Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis

Technology appraisal guidance Published June 2008

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published July 2010

Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)

Technology appraisal guidance Published February 2010

Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the first-line treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published September 2009

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Evidence-based recommendation on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage III melanoma with lymph node involvement in adults

Technology appraisal guidance Published December 2018

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults

Technology appraisal guidance Published November 2018

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma (HCC) in adults

Technology appraisal guidance Published December 2018

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

Technology appraisal guidance Published November 2018

Vandetanib for treating medullary thyroid cancer (TA550)

Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults

Technology appraisal guidance Published December 2018

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Evidence-based recommendations on nivolumab (Opdivo) for squamous cell carcinoma (SCC) of the head and neck in adults who have had platinum-based chemotherapy

Technology appraisal guidance Published November 2017

Vismodegib for treating basal cell carcinoma (TA489)

Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma (BCC; non-melanoma skin cancer; rodent ulcers) in adults

Technology appraisal guidance Published November 2017

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults

Technology appraisal guidance Published November 2017

Naltrexone–bupropion for managing overweight and obesity (TA494)

Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults

Technology appraisal guidance Published December 2017

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

Evidence-based recommendations on cladribine tablets (Mavenclad) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published December 2017

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Venetoclax for treating chronic lymphocytic leukaemia (TA487)

Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published November 2017

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy

Technology appraisal guidance Published November 2017

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2018

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Golimumab for treating non-radiographic axial spondyloarthritis (TA497)

Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults

Technology appraisal guidance Published January 2018

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab

Technology appraisal guidance Published August 2017

Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults

Technology appraisal guidance Published August 2017

Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)

NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence

Technology appraisal guidance Published August 2017

Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)

NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was

Technology appraisal guidance Published August 2017

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults

Technology appraisal guidance Published September 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin

Technology appraisal guidance Published March 2014

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)

Technology appraisal guidance Published November 2012

Alteplase for treating acute ischaemic stroke (TA264)

Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)

Technology appraisal guidance Published September 2012

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine

Technology appraisal guidance Published June 2012

Tocilizumab for the treatment of rheumatoid arthritis (TA247)

Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis

Technology appraisal guidance Published February 2012

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)

Evidence-based recommendations on rituximab (MabThera) for first-line maintenance treatment of follicular non-Hodgkin's lymphoma

Technology appraisal guidance Published June 2011